Navigation Links
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Date:5/13/2008

said Paul LaViolette, Chief Operating Officer of Boston Scientific. "With the anticipated FDA approval of the XIENCE V (PROMUS) Stent and the launch of the TAXUS Liberte Stent this year, we are excited to offer physicians and their patients two drugs on two highly deliverable platforms."

The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. The PROMUS and TAXUS Liberte(R) Stents have received CE Mark approval and are distributed in most European countries and other international markets. The XIENCE V (PROMUS) Stent is an investigational device in the U.S. and not yet approved for sale. It is currently under FDA review with an anticipated U.S. launch in 2008.

SPIRIT III is sponsored by Abbott. TAXUS, TAXUS Express2, Express, Liberte and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories Group of Companies.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance and competitive offering
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Exelixis Announces First Quarter 2008 Financial Results
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Sequenom, Inc. (Nasdaq: SQNM ) today announced ... company at the following conferences in November. ... ) Lazard Capital Markets 7th Annual ... York, NY Presentation date: Tuesday November 16, 2010 ...
... Pharmaceuticals today announced it has discovered that EVP-6124, its ... not previously seen in the scientific community: it acts ... By acting as a co-agonist and sensitizing ... amounts of naturally occurring ACh, typically found in individuals ...
Cached Medicine Technology:Sequenom to Present at Two Financial Conferences in November 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3
(Date:7/9/2014)... an innovative tool that captures heretofore hidden ways that ... a protein that makes breast cancer cells more likely ... trigger cancer,s spread in part by blocking two other ... that suggests these two disease processes could have unexpected ... July 10 issue of Nature , points to ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... has been a sharp increase in the number of ... the online, interactive service that allows patients to view ... schedule appointments, and renew prescriptions. , Over a six-year ... each year increased five-fold, while the number of ... to a study by Dr. David Gerber , ...
(Date:7/9/2014)... watching World Cup highlights, Brian Williams refreshing old school ... positions on railings. A University of Colorado Cancer Center ... shows that YouTube also allows researchers, journals, and health ... of skin cancer and prevention. , "No matter what ... how we communicate around the world," says Chante Karimkhani, ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... China is no cause for alarm , , MONDAY, April ... case of human-to-human transmission of bird flu in China. ... there,s a genetic component to human-to-human transmission of this ... suggests that there,s some genetic component to resistance in ...
... powder-free, ANAHEIM, Calif., April 7, 2008 ... year,s Association of PeriOperative,Registered Nurses (AORN) 55th Congress ... reported being "very concerned" about the surgical,complications related ... facility was powder-free. Powdered gloves have been implicated ...
... The Chehalis,Confederated Tribes will host a special ... Casino May 17 and 18, tribal officials,announced this ... Honor Veterans Benefit," will provide much needed support ... the Freedoms Foundation,s,Return to Honor Program., "We,re ...
... Media, Inc. (AMI),today said that it has made ... to be disclosed on a monthly basis to ... Agreement., The information, which includes the average ... the period April 2007,through March 2008, as well ...
... Pa., April 7, 2008 Genaera,Corporation (Nasdaq: ... Rule 4350(b)(1)(B), that the audit report included in ... fiscal year ended December 31,2007 contained an unqualified ... KPMG LLP, which included a "going concern",explanatory paragraph. ...
... Pa., April 7, 2008 Consumers who,purchased raw ... Bethlehem, Clarion,County, and Clark and Elaine Duncan,s farm ... discard it immediately due to the risk of,Listeria ... Raw milk is milk that has not been ...
Cached Medicine News:Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 2Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 3Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 4Health News:Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 3
EIA Kit for the detection of progesterone....
No cross-reaction with human pro-insulin and C-peptide....
... innovative GenePaint technology, the investigation of gene ... easier. The GenePaint system automates efficiently and ... required for performing ISH on cells or ... fixing, staining, washing and hybridization procedures. With ...
... (17alpha-OH-P) is a steroid produced in the ... defined physiological role except as a precursor ... be converted to cortisol by the sequential ... the adrenal glands and ovaries, 17alpha-OH-P can ...
Medicine Products: